I-161: Experience of Health-Care Workers (HCWs) Taking Postexposure Prophylaxis (PEP) after Occupational HIV Exposures: Findings of the HIV PEP Registry
September 26, 1998
The HIV PEP Registry was established by the CDC after the US Public Health Service first recommended in 1996 the use of combination antiretroviral therapy as prophylaxis immediately following certain occupational HIV exposures, in an effort to collect data regarding the safety and outcome of PEP. From October 17, 1996 through August 15, 1998, 432 HCWs were confidentially enrolled in a prospective manner into the Registry. Data about the types of exposure and the medium of risk exposure demonstrates:
Blood or blood product 71%
Only 14% of the HCWs with 6 week follow up were reported to manifest any laboratory abnormalities, but upon review of the abnormalities none were found to be of significance. Unfortunately, the study is unable to correlate any toxicity to any specific drug, and because there is no comparison for adverse events (HCWs with HIV exposure but who did not take PEP were not enrolled) no definitive conclusions can be made regarding the rates of occurrence of toxicity. As a result of the data gathered so far, the authors urged healthcare providers to carefully counsel individuals on PEP in order to advise about side effects and ways to manage them. Some good news: no official seroconversions were reported in the cohort. More information about The HIV PEP Registry can be obtained via phone, fax or internet:
This article was provided by TheBodyPRO. It is a part of the publication The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy.
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.